SCM
IPHA

Silverarc Capital Management’s Innate Pharma IPHA Stock Holding History

Silverarc Capital Management’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-184,046
Closed -$839K – 76
2021
Q4 		$839K Buy
+184,046
New +$979K 0.34% 63

Other funds holding IPHA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Silverarc Capital Management's IPHA Position: Q1 2022 in Review

Silverarc Capital Management sold out of Innate Pharma (IPHA) in Q1 2022, closing a stake of 184,046 shares — an estimated $839K sold.

Silverarc Capital Management first reported a position in IPHA in Q4 2021 and held it in 1 quarter. The position peaked at $839K in Q4 2021. 13 funds tracked by Wall St. Rank hold IPHA as of Q1 2022.

  • Silverarc Capital Management reported no remaining Innate Pharma position as of Q1 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 184,046 Innate Pharma shares in Q1 2022, an estimated $839K.
  • Silverarc Capital Management first reported a position in Innate Pharma in Q4 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Innate Pharma position peaked at $839K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2022.

Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.